Cargando…

Clinical features and prognosis of acute-on-chronic liver failure in patients with recompensated cirrhosis

BACKGROUND: There are few studies on acute-on-chronic liver failure (ACLF) in patients with recompensated cirrhosis. This study was aimed to investigate the clinical features of ACLF patients with recompensated cirrhosis. METHODS: A total of 461 ACLF patients were enrolled and divided into three gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Haixia, Cao, Yingying, Yu, Zhenjun, Huang, Yue, Liu, Fang, Gao, Yanying, Qiu, Shaotian, Han, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510206/
https://www.ncbi.nlm.nih.gov/pubmed/37726716
http://dx.doi.org/10.1186/s12876-023-02956-4
_version_ 1785107917102383104
author Yuan, Haixia
Cao, Yingying
Yu, Zhenjun
Huang, Yue
Liu, Fang
Gao, Yanying
Qiu, Shaotian
Han, Tao
author_facet Yuan, Haixia
Cao, Yingying
Yu, Zhenjun
Huang, Yue
Liu, Fang
Gao, Yanying
Qiu, Shaotian
Han, Tao
author_sort Yuan, Haixia
collection PubMed
description BACKGROUND: There are few studies on acute-on-chronic liver failure (ACLF) in patients with recompensated cirrhosis. This study was aimed to investigate the clinical features of ACLF patients with recompensated cirrhosis. METHODS: A total of 461 ACLF patients were enrolled and divided into three groups: compensated, recompensated, and decompensated cirrhosis with ACLF. The baseline clinical data and 1-year survival rates were compared among the three groups. RESULTS: Compared with the decompensated group, in the recompensated group, the levels of hemoglobin, albumin, and serum sodium were significantly higher and the white blood cell count, international normalized ratio, and incidence of respiratory failure were significantly lower; there were no evident differences in other organ failures. The proportion of patients with ACLF grade 3 and 1-year survival rates significantly differed between the two groups. Conversely, compared with the compensated group, in the recompensated group, the platelet and total bilirubin levels were significantly lower and the proportion of patients with ACLF grade 1 was significantly higher. However, other clinical indicators or 1-year survival rates did not significantly differ between the two groups. CONCLUSIONS: Compared with patients who developed ACLF with decompensated cirrhosis, those who developed ACLF with recompensated cirrhosis had a less severe condition, lower incidence of respiratory failure, and better 1-year prognosis. However, the baseline clinical features and prognosis were similar between ACLF patients with recompensated and compensated cirrhosis. TRIAL REGISTRATION: Chinese clinical trials registry: ChiCTR1900021539. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-023-02956-4.
format Online
Article
Text
id pubmed-10510206
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105102062023-09-21 Clinical features and prognosis of acute-on-chronic liver failure in patients with recompensated cirrhosis Yuan, Haixia Cao, Yingying Yu, Zhenjun Huang, Yue Liu, Fang Gao, Yanying Qiu, Shaotian Han, Tao BMC Gastroenterol Research BACKGROUND: There are few studies on acute-on-chronic liver failure (ACLF) in patients with recompensated cirrhosis. This study was aimed to investigate the clinical features of ACLF patients with recompensated cirrhosis. METHODS: A total of 461 ACLF patients were enrolled and divided into three groups: compensated, recompensated, and decompensated cirrhosis with ACLF. The baseline clinical data and 1-year survival rates were compared among the three groups. RESULTS: Compared with the decompensated group, in the recompensated group, the levels of hemoglobin, albumin, and serum sodium were significantly higher and the white blood cell count, international normalized ratio, and incidence of respiratory failure were significantly lower; there were no evident differences in other organ failures. The proportion of patients with ACLF grade 3 and 1-year survival rates significantly differed between the two groups. Conversely, compared with the compensated group, in the recompensated group, the platelet and total bilirubin levels were significantly lower and the proportion of patients with ACLF grade 1 was significantly higher. However, other clinical indicators or 1-year survival rates did not significantly differ between the two groups. CONCLUSIONS: Compared with patients who developed ACLF with decompensated cirrhosis, those who developed ACLF with recompensated cirrhosis had a less severe condition, lower incidence of respiratory failure, and better 1-year prognosis. However, the baseline clinical features and prognosis were similar between ACLF patients with recompensated and compensated cirrhosis. TRIAL REGISTRATION: Chinese clinical trials registry: ChiCTR1900021539. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-023-02956-4. BioMed Central 2023-09-19 /pmc/articles/PMC10510206/ /pubmed/37726716 http://dx.doi.org/10.1186/s12876-023-02956-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yuan, Haixia
Cao, Yingying
Yu, Zhenjun
Huang, Yue
Liu, Fang
Gao, Yanying
Qiu, Shaotian
Han, Tao
Clinical features and prognosis of acute-on-chronic liver failure in patients with recompensated cirrhosis
title Clinical features and prognosis of acute-on-chronic liver failure in patients with recompensated cirrhosis
title_full Clinical features and prognosis of acute-on-chronic liver failure in patients with recompensated cirrhosis
title_fullStr Clinical features and prognosis of acute-on-chronic liver failure in patients with recompensated cirrhosis
title_full_unstemmed Clinical features and prognosis of acute-on-chronic liver failure in patients with recompensated cirrhosis
title_short Clinical features and prognosis of acute-on-chronic liver failure in patients with recompensated cirrhosis
title_sort clinical features and prognosis of acute-on-chronic liver failure in patients with recompensated cirrhosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510206/
https://www.ncbi.nlm.nih.gov/pubmed/37726716
http://dx.doi.org/10.1186/s12876-023-02956-4
work_keys_str_mv AT yuanhaixia clinicalfeaturesandprognosisofacuteonchronicliverfailureinpatientswithrecompensatedcirrhosis
AT caoyingying clinicalfeaturesandprognosisofacuteonchronicliverfailureinpatientswithrecompensatedcirrhosis
AT yuzhenjun clinicalfeaturesandprognosisofacuteonchronicliverfailureinpatientswithrecompensatedcirrhosis
AT huangyue clinicalfeaturesandprognosisofacuteonchronicliverfailureinpatientswithrecompensatedcirrhosis
AT liufang clinicalfeaturesandprognosisofacuteonchronicliverfailureinpatientswithrecompensatedcirrhosis
AT gaoyanying clinicalfeaturesandprognosisofacuteonchronicliverfailureinpatientswithrecompensatedcirrhosis
AT qiushaotian clinicalfeaturesandprognosisofacuteonchronicliverfailureinpatientswithrecompensatedcirrhosis
AT hantao clinicalfeaturesandprognosisofacuteonchronicliverfailureinpatientswithrecompensatedcirrhosis